Proceedings of 33rd Annual General Meeting
The announcement is a routine disclosure about the AGM proceedings and resolutions, which have a limited immediate impact on the company's operations or stock price.
The announcement primarily discusses the proceedings of the Annual General Meeting and the resolutions passed, without indicating a clear positive or negative impact.
* The 33rd Annual General Meeting of Krebs Biochemicals and Industries Limited was held on Friday, September 26, 2025, at 11:30 a.m. * All directors, including the Chairman of the Audit and Nomination & Remuneration Committee, CFO, and Company Secretary, were present. * Representatives of the Statutory Auditors, Secretarial Auditors, and the Scrutinizer were also present. * Dr. R. T. Ravi, Chairman, presided over the meeting and addressed the members. * The meeting covered the following agenda items: * Adoption of Audited Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement for the year ended March 31, 2025. * Re-appointment of Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya as Directors. * Appointment of Statutory Auditors and fixing their remuneration. * Appointment of Mr. Manish Kumar Jain as Director, and as Managing Director and CEO of the Company. * Approval for Related Party Transactions with Ipca Laboratories Limited. * Ratification of remuneration payable to the Cost Auditors. * Appointment of M/s. DSMR & Associates as the Secretarial Auditor for 5 years commencing from FY 2025-26. * The e-voting process was conducted from September 23, 2025, to September 25, 2025. * The meeting concluded at 11:55 a.m.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.